HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Satoshi Fujii Selected Research

ezrin

1/2018Abundant tumor promoting stromal cells in lung adenocarcinoma with hypoxic regions.
11/2017Immunohistochemical and genetic characteristics of lung cancer mimicking organizing pneumonia.
1/2017Concomitant expression of ezrin and HER2 predicts distant metastasis and poor prognosis of patients with salivary gland carcinomas.
10/2016Microenvironmental changes in the progression from adenocarcinoma in situ to minimally invasive adenocarcinoma and invasive lepidic predominant adenocarcinoma of the lung.
7/2016The difference in Ezrin-pAkt signaling axis between lepidic and papillary predominant invasive adenocarcinomas of the lung.
1/2016Aggressive tumor microenvironment of solid predominant lung adenocarcinoma subtype harboring with epidermal growth factor receptor mutations.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Satoshi Fujii Research Topics

Disease

83Neoplasms (Cancer)
04/2024 - 03/2003
17Neoplasm Metastasis (Metastasis)
08/2023 - 02/2008
16Colorectal Neoplasms (Colorectal Cancer)
05/2023 - 01/2007
15Atherosclerosis
03/2016 - 03/2002
13Breast Neoplasms (Breast Cancer)
09/2023 - 08/2003
12Esophageal Squamous Cell Carcinoma
11/2022 - 01/2015
9Infections
08/2023 - 06/2007
9Hypertension (High Blood Pressure)
05/2020 - 05/2002
8Squamous Cell Carcinoma (Epidermoid Carcinoma)
03/2024 - 11/2008
8Pancreatic Neoplasms (Pancreatic Cancer)
02/2024 - 03/2003
8Stomach Neoplasms (Stomach Cancer)
05/2023 - 04/2008
8Insulin Resistance
01/2016 - 08/2004
7Esophageal Neoplasms (Esophageal Cancer)
02/2024 - 02/2016
7Inflammation (Inflammations)
07/2022 - 05/2002
7Coronary Artery Disease (Coronary Atherosclerosis)
03/2016 - 06/2007
6Hypoxia (Hypoxemia)
07/2022 - 12/2013
6Lung Neoplasms (Lung Cancer)
10/2020 - 06/2007
6Carcinoma (Carcinomatosis)
02/2019 - 06/2010
5COVID-19
02/2024 - 01/2021
5Lymphatic Metastasis
11/2022 - 01/2007
5Adenocarcinoma of Lung
12/2018 - 01/2016
5Pressure Ulcer (Bedsore)
11/2018 - 05/2009
5Rectal Neoplasms (Rectal Cancer)
12/2016 - 11/2011
5Hepatocellular Carcinoma (Hepatoma)
06/2013 - 09/2003
4Adenocarcinoma
01/2020 - 01/2016
4Wounds and Injuries (Trauma)
11/2018 - 07/2010
4Tetanus
05/2016 - 05/2008
4Squamous Cell Carcinoma of Head and Neck
03/2016 - 11/2012
4Obesity
01/2016 - 08/2004
4Thrombosis (Thrombus)
12/2014 - 06/2003
4Fibrosis (Cirrhosis)
11/2011 - 08/2004
4Type 2 Diabetes Mellitus (MODY)
11/2011 - 03/2005
3Acute Kidney Injury (Acute Renal Failure)
04/2024 - 12/2021
3Bacteremia
12/2023 - 11/2017
3Critical Illness (Critically Ill)
11/2023 - 06/2023
3Neutropenia
01/2022 - 02/2008
3Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
10/2020 - 01/2016
3Body Weight (Weight, Body)
01/2016 - 02/2010
3Myocardial Infarction
11/2011 - 08/2007

Drug/Important Bio-Agent (IBA)

18Proteins (Proteins, Gene)FDA Link
11/2023 - 04/2008
12Plasminogen Activator Inhibitor 1IBA
12/2013 - 09/2003
9Biomarkers (Surrogate Marker)IBA
01/2021 - 03/2010
9Plasminogen InactivatorsIBA
11/2012 - 04/2004
7VancomycinFDA LinkGeneric
11/2023 - 01/2013
7Trastuzumab (Herceptin)FDA Link
11/2021 - 05/2011
7Cadherins (E-Cadherin)IBA
01/2021 - 04/2008
6Indicators and Reagents (Reagents)IBA
02/2024 - 08/2003
6Formaldehyde (Formol)FDA Link
05/2023 - 06/2013
6ParaffinIBA
01/2022 - 11/2012
6ezrinIBA
01/2018 - 01/2016
5Glucose (Dextrose)FDA LinkGeneric
09/2023 - 03/2007
5human ERBB2 proteinIBA
05/2023 - 01/2014
5Carbonic Anhydrase IXIBA
01/2021 - 04/2013
5Interleukin-6 (Interleukin 6)IBA
01/2021 - 09/2003
5KalininIBA
07/2019 - 04/2013
5Histones (Histone)IBA
01/2012 - 03/2003
4Oxygen (Dioxygen)IBA
07/2022 - 09/2008
4Docetaxel (Taxotere)FDA Link
01/2022 - 02/2008
4RNA (Ribonucleic Acid)IBA
12/2021 - 01/2016
4MicroRNAs (MicroRNA)IBA
12/2021 - 01/2016
4CytokinesIBA
01/2021 - 09/2003
4dihydroceramide desaturaseIBA
10/2020 - 01/2016
4Small Interfering RNA (siRNA)IBA
01/2020 - 04/2008
4Messenger RNA (mRNA)IBA
01/2020 - 03/2005
4Ointments (Pastes)IBA
11/2018 - 07/2010
4IodineIBA
01/2014 - 05/2009
4Apolipoproteins E (ApoE)IBA
04/2013 - 03/2002
3AnticoagulantsIBA
02/2024 - 12/2014
3AminoglycosidesIBA
08/2023 - 01/2021
3Transcription Factors (Transcription Factor)IBA
06/2022 - 02/2008
3Linezolid (Zyvox)FDA Link
01/2022 - 01/2013
3Eosine Yellowish-(YS) (Eosin)IBA
01/2022 - 01/2007
3Monoclonal AntibodiesIBA
01/2021 - 11/2017
3Epidermal Growth Factor (EGF)IBA
01/2021 - 12/2012
3DNA (Deoxyribonucleic Acid)IBA
12/2020 - 09/2018
3SphingolipidsIBA
10/2020 - 05/2015
3Transforming Growth Factors (Transforming Growth Factor)IBA
01/2020 - 08/2004
3Cetuximab (Erbitux)FDA Link
01/2020 - 12/2012
3AntibodiesIBA
05/2019 - 12/2012
3GemininIBA
02/2019 - 06/2010
3Hyaluronic Acid (Hyaluronan)IBA
11/2018 - 02/2015
3SphingosineIBA
08/2016 - 12/2013
3LigandsIBA
07/2016 - 05/2011
3HDL CholesterolIBA
01/2016 - 03/2007
3Codon (Codons)IBA
09/2013 - 12/2012
3ApolipoproteinsIBA
04/2013 - 03/2002
3AcidsIBA
01/2011 - 09/2003
3Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
05/2010 - 09/2003
3ChromatinIBA
06/2008 - 03/2003
3Plasminogen Activators (Plasminogen Activator)IBA
01/2007 - 06/2003
2Immune Checkpoint InhibitorsIBA
03/2024 - 06/2023
2NivolumabIBA
03/2024 - 06/2023
2Long Noncoding RNAIBA
02/2024 - 01/2020

Therapy/Procedure

30Therapeutics
04/2024 - 01/2013
18Drug Therapy (Chemotherapy)
08/2023 - 02/2008
12Chemoradiotherapy
02/2024 - 11/2011
10Neoadjuvant Therapy
02/2024 - 01/2013
7Radiotherapy
08/2023 - 02/2008
3Lymph Node Excision (Lymph Node Dissection)
08/2023 - 01/2019
2Esophagectomy
02/2024 - 01/2019